Chinook Therapeutics, Inc. Profile Avatar - Palmy Investing

Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…

Biotechnology
US, Seattle [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Chinook Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of KDNY's Analysis
CIK: 1435049 CUSIP: 16961L106 ISIN: US00739L1017 LEI: - UEI: -
Secondary Listings
KDNY has no secondary listings inside our databases.